

O'CONNOR et al
Serial No. 09/701,080

(a) (i) incubating said first polypeptide with said second polypeptide *in vitro* under conditions which allow the first polypeptide to bind to the second polypeptide to form a complex; and bringing the complex thus formed into contact with a candidate compound; or

(ii) incubating said first polypeptide with said second polypeptide *in vitro* in the presence of a candidate compound under conditions which would allow the first polypeptide to bind to the second polypeptide in the absence of the candidate compound; and

E'onncl'd. (b) determining if said candidate compound inhibits binding of the first polypeptide to the second polypeptide;

wherein said first polypeptide comprises a Transcriptional Adaptor Motif (TRAM) sequence of any one of the sequences shown in SEQ ID NO: 3 to 9 and said second polypeptide is a human papillomavirus (HPV) polypeptide E6 of HPV-16 or HPV-18 comprising a sequence which binds to a said TRAM sequence.

E2 ⁴ ~~43~~ (Twice Amended) The method according to claim ² ~~41~~ wherein said eukaryotic polypeptide is selected from mdm2 comprising a sequence of SEQ ID NO:6 or 7, CREB binding protein (CBP) comprising a sequence of SEQ ID NO:3, 4 or 5, and p300 comprising a sequence of SEQ ID NO:8 or 9.

E3 ⁵ ~~53~~ (Amended) The method according to claim ¹ ~~36~~ wherein the first polypeptide is CREB binding protein (CBP) comprising a sequence of SEQ ID NO:3, 4 or 5.

O'CONNOR et al
Serial No. 09/701,080

⁶
~~54~~ (Amended) The method according to claim ~~36~~¹ wherein the sequence which binds said TRAM sequence is located within the second zinc finger of HPV-16 or -18 E6 protein.

⁷
~~56~~ (Amended) The method according to claim ~~36~~¹ wherein said first polypeptide is p300 comprising a sequence of SEQ ID NO:8 or 9.

⁸
~~57~~ (Amended) The method according to claim ~~36~~¹ wherein said second polypeptide comprises the sequence of amino acids 100 to 147 of SEQ ID NO: 18.

⁹
~~58~~ (New) The method according to claim ~~36~~¹ wherein the first polypeptide is mdm2 comprising a sequence of SEQ ID NO:6 or SEQ ID NO:7.

IN THE ABSTRACT:

After page 57, add the Abstract of the Disclosure submitted herewith on separate sheets.

REMARKS

Reconsideration of this application and entry of the forgoing amendments are respectfully requested.

Claims 36, 43, 53, 54, 56 and 57 have been revised to define the invention with additional clarity. Claims 40, 45, 46 and 55 have been cancelled, without prejudice. New claim 58 finds support in the same manner as claim 43.